TY - JOUR
T1 - Importance of luminal membrane mesothelin expression in intraductal papillary mucinous neoplasms
AU - Einama, Takahiro
AU - Kamachi, Hirofumi
AU - Nishihara, Hiroshi
AU - Homma, Shigenori
AU - Kanno, Hiromi
AU - Ishikawa, Marin
AU - Kawamata, Futoshi
AU - Konishi, Yuji
AU - Sato, Masanori
AU - Tahara, Munenori
AU - Okada, Kuniaki
AU - Muraoka, Shunji
AU - Kamiyama, Toshiya
AU - Taketomi, Akinobu
AU - Matsun, Yoshihiro
AU - Furukawa, Hiroyuki
AU - Todo, Satoru
N1 - Publisher Copyright:
© 2014, Spandidos Publications. All rights reserved.
PY - 2015
Y1 - 2015
N2 - The present study demonstrated that luminal membrane mesothelin expression is a reliable prognostic factor in gastric cancer. Intraductal papillary mucinous neoplasms (IPMNs) often exhibit a spectrum of dysplasia, ranging between adenoma and carcinoma. Therefore, an immunohistochemical analysis of mesothelin expression in IPMN was performed in the present study, focusing on the localization of mesothelin. IPMNs were classified into two groups, IPMNs associated with invasive carcinoma and low-high (L-H) grade dysplasias. The tumors were classified as mesothelin-positive or -negative and in the mesothelin-positive cases, the localization of mesothelin was evaluated as luminal membrane- or cytoplasmic-positive. Among the 37 IPMNs, mesothelin expression was observed in 21 samples (56.8%), including 46.2% (12 out of 26) of the L-H dysplasia and 81.8% (9 out of 11) of the invasive carcinoma samples (P=0.071). Luminal membrane localization was observed in 10 samples (27%), including 15.4% (4/26) of the L-H dysplasia samples and 54.5% (6 out of 11) of the invasive carcinoma samples (P=0.022). Six patients experienced post-operative recurrence, with five of the recurrent tumors exhibiting mesothelin expression and all six exhibiting luminal membrane localization. It was concluded that immunohistochemical examinations for mesothelin expression and localization are clinically useful for prognostic assessments and decision making regarding further treatment subsequent to surgical procedures in patients with IPMN.
AB - The present study demonstrated that luminal membrane mesothelin expression is a reliable prognostic factor in gastric cancer. Intraductal papillary mucinous neoplasms (IPMNs) often exhibit a spectrum of dysplasia, ranging between adenoma and carcinoma. Therefore, an immunohistochemical analysis of mesothelin expression in IPMN was performed in the present study, focusing on the localization of mesothelin. IPMNs were classified into two groups, IPMNs associated with invasive carcinoma and low-high (L-H) grade dysplasias. The tumors were classified as mesothelin-positive or -negative and in the mesothelin-positive cases, the localization of mesothelin was evaluated as luminal membrane- or cytoplasmic-positive. Among the 37 IPMNs, mesothelin expression was observed in 21 samples (56.8%), including 46.2% (12 out of 26) of the L-H dysplasia and 81.8% (9 out of 11) of the invasive carcinoma samples (P=0.071). Luminal membrane localization was observed in 10 samples (27%), including 15.4% (4/26) of the L-H dysplasia samples and 54.5% (6 out of 11) of the invasive carcinoma samples (P=0.022). Six patients experienced post-operative recurrence, with five of the recurrent tumors exhibiting mesothelin expression and all six exhibiting luminal membrane localization. It was concluded that immunohistochemical examinations for mesothelin expression and localization are clinically useful for prognostic assessments and decision making regarding further treatment subsequent to surgical procedures in patients with IPMN.
KW - Intraductal papillary mucinous neoplasms
KW - Luminal membrane expression
KW - Mesothelin
UR - http://www.scopus.com/inward/record.url?scp=84923169592&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84923169592&partnerID=8YFLogxK
U2 - 10.3892/ol.2015.2969
DO - 10.3892/ol.2015.2969
M3 - Article
AN - SCOPUS:84923169592
SN - 1792-1074
VL - 9
SP - 1583
EP - 1589
JO - Oncology Letters
JF - Oncology Letters
IS - 4
ER -
